Please assess the completion status of the following clinical trial:

Trial Title: Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary hyperparathyroidism~* Scheduled for parathyroid surgery~* Age \>40~* Ability to participate in all tests included in the study model~* Signed consent~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Fertile woman not using contraceptives (IUD or pills)~* Impaired kidney function, GFR \< 40 ml/min~* Intolerance to Mimpara®~* Previously treated with Mimpara®~* Participating in other ongoing clinical study~* Epilepsy~* Severe hepatic impairment~* Hypotension~* Heart failure (NYHA class 3-4, symptoms with minimal exertion)~* Medication with ketoconazole (oral) or tricyclic antidepressants

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).